Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Receives $4.67 Average PT from Analysts

Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTXGet Rating) have earned an average recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $4.00.

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group lowered Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Bank of America lowered Neoleukin Therapeutics from a “buy” rating to an “underperform” rating in a research note on Monday, September 12th. Mizuho lowered Neoleukin Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $21.00 to $2.00 in a research note on Tuesday. Canaccord Genuity Group reiterated a “hold” rating on shares of Neoleukin Therapeutics in a research note on Tuesday. Finally, Guggenheim lowered Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday.

Neoleukin Therapeutics Price Performance

Neoleukin Therapeutics stock opened at $0.42 on Tuesday. The stock’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.92. Neoleukin Therapeutics has a one year low of $0.38 and a one year high of $5.95. The firm has a market cap of $17.89 million, a PE ratio of -0.39 and a beta of 1.18.

Institutional Investors Weigh In On Neoleukin Therapeutics

Hedge funds have recently modified their holdings of the company. Adviser Investments LLC boosted its holdings in shares of Neoleukin Therapeutics by 347.6% during the 1st quarter. Adviser Investments LLC now owns 46,817 shares of the company’s stock valued at $88,000 after acquiring an additional 36,357 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Neoleukin Therapeutics during the 1st quarter worth about $85,000. Shay Capital LLC acquired a new position in Neoleukin Therapeutics during the 1st quarter worth about $52,000. Kestra Private Wealth Services LLC lifted its holdings in Neoleukin Therapeutics by 100.0% during the 1st quarter. Kestra Private Wealth Services LLC now owns 24,000 shares of the company’s stock worth $45,000 after buying an additional 12,000 shares during the period. Finally, Virtu Financial LLC acquired a new position in Neoleukin Therapeutics during the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 49.19% of the company’s stock.

Neoleukin Therapeutics Company Profile

(Get Rating)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

See Also

Analyst Recommendations for Neoleukin Therapeutics (NASDAQ:NLTX)

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.